Pharmaceutical giant Roche (SWX: ROG), based in Switzerland, has announced an agreement to acquire innovative diagnostic technology from UK-headquartered LumiraDx (OTCMKTS: LMDXF). The transaction, expected to close in mid-2024, involves an upfront payment of $295 million, complemented by up to an additional $55 million to support LumiraDx’s point-of-care business during the period leading up to the deal’s completion.
The acquisition includes a versatile platform that integrates multiple diagnostic modalities, enabling a broad array of immunoassay and clinical chemistry tests that remain stable at room temperature and address various disease areas. This move is set to bolster Roche’s diagnostic portfolio and its capabilities in decentralized healthcare solutions.- Flcube.com
